Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

[18F]MK-6240 ([18F]MNI-946)

Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Tau
Use
Monitoring
Pharmacodynamic/response
Susceptibility/risk
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

The recent development of a PET tracer,[18F]MK-6240(an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology. The investigators will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation. This study of tau PET using [18F]MK-6240 is performed in conjunction with DIAN and DIAN Extended Registry (DIAN-EXR).

Target Population/ Population Being Studied

individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation

Length of Current Trial
12 years
Number of Trial Participants

200

Estimated Trial Completion
June 2024
What is Required from Patients

injection of radioactive tracers, mild discomfort, in clinic visit

What is Required from the Health System

PET technician, PET scanner, dyes

Sponsor

Washington University School of Medicine

  1. “Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein.” ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT03071224?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=4&rank=34

  2. “Study of Tau Imaging With the Use of [18F]MK-6240 Tracer (MKADAD).” ClinicalTrials.gov. Accessed October 11, 2019. https://clinicaltrials.gov/ct2/show/NCT04104659?term=biomarker&recrs=adf&cond=Alzheimer+Disease&draw=20&rank=165